News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Versartis, Inc. (VSAR) Announces Closing Of Its Initial Public Offering And Full Exercise Of Over-Allottment Option


3/27/2014 9:28:26 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif., March 26, 2014 (GLOBE NEWSWIRE) -- Versartis, Inc., (Nasdaq:VSAR) an endocrine-focused biopharmaceutical company, today announced the closing of its initial public offering of 6,900,000 shares of its common stock at a public offering price of $21 per share, which included 900,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares. The shares began trading on the NASDAQ Global Select Market under the ticker symbol "VSAR" on March 21, 2014. Versartis estimates net proceeds from the offering to be approximately $132.4 million after deducting underwriting discounts and commissions and estimated offering expenses. Morgan Stanley and Citigroup acted as joint book-running managers for the offering. Cowen & Company acted as lead manager and Canaccord Genuity acted as co-manager.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES